Allison Betof Warner, MD, Stanford Cancer Center, Stanford, CA, discusses current treatments available for the management of brain metastases in patients with advanced melanoma, which occur in 30 to 40% of patients at the time of diagnosis. Results from the CheckMate 204 (NCT02320058) and ABC (NCT02374242) trials have indicated ipilimumab and nivolumab as frontline treatments. Patients with BRAF V600 mutations undergo targeted therapy with either a combination of dabrafenib and trametinib or encorafenib and binimetinib. Ensuring its efficacy as a long-term treatment option remain a challenge in this area. This interview took place at the Society for Melanoma Research (SMR) 2024 Annual Meeting in New Orleans, LA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.